cAMP Response Element-Binding Protein- and Phosphorylation-Dependent Regulation of Tyrosine Hydroxylase by PAK4: Implications for Dopamine Replacement Therapy
So-Yoon Won, Soon-Tae You, Seung-Won Choi, Catriona McLean, Eun-Young Shin, and Eung-Gook Kim
Abstract
Parkinson’s disease (PD) is characterized by a progressive loss of dopamine-producing neurons in the midbrain, which results in decreased dopamine levels accompanied by movement symptoms. Oral administration of l-3,4-dihydroxyphenylalanine (L-dopa), the precursor of dopamine, provides initial symptomatic relief, but abnormal involuntary movements develop later. A deeper understanding of the regulatory mechanisms underlying dopamine homeostasis is thus critically needed for the development of a successful treatment. Here, we show that p21-activated kinase 4 (PAK4) controls dopamine levels. Constitutively active PAK4 (caPAK4) stimulated transcription of tyrosine hydroxylase (TH) via the cAMP response element-binding protein (CREB) transcription factor. Moreover, caPAK4 increased the catalytic activity of TH through its phosphorylation of S40, which is essential for TH activation. Consistent with this result, in human midbrain tissues, we observed a strong correlation between phosphorylated PAK4S474, which represents PAK4 activity, and phosphorylated THS40, which reflects their enzymatic activity. Our findings suggest that targeting the PAK4 signaling pathways to restore dopamine levels may provide a new therapeutic approach in PD.
INTRODUCTION
Parkinson’s disease (PD) is an age-dependent disorder characterized by progressive degeneration of dopamine (DA) neurons in the substantia nigra (SN) pars compacta, leading to a decrease in DA levels in the striatum (Dauer and Przedborski, 2003). Most patients appear to experience motor symptoms when dopamine levels drop by 60% to 80% in the brain (Marsden, 1990). The resultant major symptoms include tremor, akinesia, postural instability and bradykinesia (Marsden, 1990). Currently, initial treatment starts with oral administration of l-3,4-dihydroxyphenylalanine (L-dopa), which alleviates motor symptoms, but L-dopa-induced dyskinesia subsequently develops (Mones et al., 1970). Therefore, there is an urgent need for a better method of DA replacement in patients with PD.
Tyrosine hydroxylase (TH) is the rate-limiting enzyme of DA synthesis (Tekin et al., 2014; Zhu et al., 2012); thus, regulation of TH protein levels and activity represent a central means for controlling DA synthesis. The TH gene contains a cAMP response element (CRE) and an activating protein-1 (AP-1)-binding site in its promoter (Ghee et al., 1998). CRE is involved in the basal and inducible transcription of the TH gene. TH activity is modulated by multiple protein kinases that phosphorylate TH at S19, S31 and S40; of these, S40 represents a key residue for TH activation (Haycock and Haycock, 1991; Ramsey and Fitzpatrick, 1998). A reduction in TH activity results in diminished DA synthesis and contributes to motor impairment in PD; thus, dysregulation of TH activity is an essential component of the pathogenesis of PD. Therefore, a therapeutic strategy aimed at improving TH expression and activity in PD is of widespread interest.
p21-activated kinase 4 (PAK4) stimulates cAMP response element-binding protein (CREB) transcriptional activity (Won et al., 2016), which promotes transcription of the TH gene; thus, PAK4 may regulate TH expression via CREB. Moreover, S40 of TH is compatible with the consensus motif for PAK4-mediated phosphorylation (Rennefahrt et al., 2007). We therefore sought to investigate the role of PAK4 as an upstream regulator of TH and examined its implications in PD.
MATERIALS AND METHODS
Immunohistochemistry of human brain tissue
Human tissue was obtained from the Victoria Brain Bank Network (Australia) (Supplementary Table S1). Experiments were performed in accordance with a protocol approved by the Ethics Review Committee of the Institutional Review Board of Chungbuk National University (approval No. CBNU-IRB-2011-T01). Paraffin-embedded human brain tissue slices were deparaffinized in xylene and subjected to citrate antigen retrieval prior to immunohistochemical analysis. For light microscopy, brain tissues were incubated with a biotin-conjugated secondary antibody followed by streptavidin-conjugated HRP (VECTASTAIN ABC Kits; Vector Laboratories, USA). Immunostaining was visualized by incubating samples in a 0.1 M-PB solution containing 0.05% diaminobenzidine-HCl (DAB) and 0.003% hydrogen peroxide. To coimmunostain pPAK4 with pTHS40, brain tissues were incubated with alkaline phosphatase-conjugated secondary antibodies (VECTASTAIN ABC Kits). Immunostaining was visualized using either Alkaline Phosphatase Substrate Kit I (red) or Alkaline Phosphatase Substrate Kit III (blue) (VECTASTAIN ABC Kits).
Cell cultures
Primary rat midbrain neuron cultures were produced as previously described (Nam et al., 2015). PC12 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and antibiotics in a humidified 5% CO2 incubator at 37°C.
Plasmid construction
The generation of wild type PAK4 (WT-PAK4) and caPAK4 (PAK4S445N/S474E) tagged with N-terminal 3×-Myc was previously described (Park et al., 2013). TH-alanine (A) mutants for serine (S) 19, 31 and 40 were produced by site-specific mutagenesis using a Quick Change Site-Directed Mutagenesis Kit (Stratagene California, USA).
siRNAs
siRNAs for rat CREB #1, UCAAGGAGGCCUUCCUACA; #2, UCUAGUGCCCAGCAACCAA and scrambled siRNA were purchased from Bioneer (Korea). CREB siRNAs (100 nM) were transfected using Lipofectamine LTX (Invitrogen, USA) for 48 h.
Transfection
For transient transfection, a mixture of DNA or siRNA and Lipofectamine 2000 reagent (Invitrogen) was prepared according to the manufacturer’s instructions and incubated with cells for the indicated times.
CRE-reporter assay
To assess the effects of PAK4, PC12 cells were cotransfected for 24 h with WT-PAK4 or caPAK4 plus the TH-luciferase reporter (30 ng), kindly provided by professor. Dr. Myung Ae Lee (Ajou University Medical Center, Suwon, Korea) (Kim et al., 2003) and Renilla luciferase (20 ng). The Renilla luciferase vector was used as an internal control. The reporter assay was performed in 24-well plates in triplicate. Luciferase activity was measured using a Dual-Luciferase Reporter assay system (Promega, USA) according to the manufacturer’s protocol.
Immunoprecipitation
Cells were harvested in lysis buffer supplemented with protease inhibitors. Lysates were rotated at 4°C for 1 h and then centrifuged at 14,000 rpm for 20 min. The supernatants were then immunoprecipitated using an anti-PAK4 antibody at 4°C for 18 h. Immunoprecipitants were collected by adding protein-G agarose and washed five times with lysis buffer. Immunoblotting analysis was performed using an anti-TH antibody.
In vitro kinase assay
Expressed His-TH mutants were purified using a Ni-NTA column. His-TH was incubated with or without GST-PAK4 (Active Motif, USA) in kinase assay buffer (20 mM Tris-HCl, pH 8.0, 10 mM MgCl2, and 1 mM dithiothreitol) containing 100 mM ATP and 5 cCi [γ-32P] ATP (PerkinElmer, USA) for 30 min at 30°C. To discriminate between autophosphorylated PAK4 and phosphorylated TH, GST-PAK4 (active-PAK4) alone was included in the reaction. Following electrophoretic separation of the proteins, phosphorylation of the target proteins was evaluated using autoradiography and immunoblotting.
Dopamine analysis
PC12 cells were seeded in 6-well culture plates at a density of 1 × 105 cells per well. Cells were transfected with CREB siRNA (100 nM), WT-PAK4 (0.5 μg) or caPAK4 (0.5 μg) and incubated for 48 h. Culture media were collected and centrifuged at 10,000g for 20 s at 4°C. The supernatants were used to measure the amount of extracellular dopamine. Cell pellets were used for measurement of intracellular dopamine. Dopamine was measured using a dopamine ELISA Kit (BioVision, USA).
Immunoblotting and quantification
Protein extracts were prepared as previously described. The immunoblots were visualized using HRP-conjugated secondary antibodies against IgG and a chemiluminescent substrate (Thermo Fisher Scientific, Norway). For quantification of protein levels, the density of each band on the immunoblots was quantified using the ImageJ software (National Institutes of Health, USA). Background values were subtracted from all images.
Statistical and image analysis
ImageJ was used to quantify the intensity of immunofluorescence signals and band densities from immunoblots. All data were analyzed using GraphPad Prism 6 software (GraphPad Software, USA). Data are presented as the mean ± SEM from at least three biologically independent experiments. Representative images were taken from at least three biologically independent experiments with similar results. Student’s t-tests or ANOVA with Student–Newman–Keuls analysis tests were used to assess statistical significance.
RESULTS
caPAK4 increases the promoter activity of the TH gene via the CREB transcription factor
PAK4 stimulates transcriptional activity of CREB via CREB regulated transcription coactivator 1 (CRTC1) (Won et al., 2016), and the TH promoter contains a CRE site for CREB (Piech-Dumas and Tank, 1999). Thus, PAK4 might upregulate TH levels via CREB. To test this idea, we examined the effect of PAK4 on the activity of the TH promoter. Constitutively active PAK4 (caPAK4) elevated the activity of the TH promoter ~8-fold compared to controls in PC12 cells, as measured by luciferase reporter activity (Fig. 1A). Wild type PAK4 (WT-PAK4) also increased activity ~3-fold but to a lesser extent than caPAK4 (Fig. 1A). caPAK4 increased TH promoter activity in a dose-dependent manner (Fig. 1B). CREB binds to the CRE on the TH promoter and regulates its transcription in rat midbrain DA cells (Ghee et al., 1998). To examine the involvement of CREB in the effect of caPAK4 on TH transcription, we used a TH promoter in which the CRE site was deleted (TH-△CRE), as illustrated in Fig. 1C.
When the TH promoter containing this CRE mutant was expressed, the reporter activity for this promoter was decreased to approximately half of that for the WT TH promoter (Fig. 1D). Collectively, these results indicate that PAK4 upregulates transcription of TH via CREB. Next, we examined whether PAK4 increases DA production because TH is the rate-limiting enzyme in DA synthesis. Expression of WT-PAK4 or caPAK4 increased levels of both intracellular and extracellular secreted DA (Fig. 1E). When CREB was knocked down by two different siRNAs, caPAK4-induced DA synthesis was reduced to a basal level (Fig. 1F). Finally, to determine whether pPAK4 and TH are correlated at the cellular level, we performed costaining for pPAK4, an index of PAK4 activity, and TH in postmortem brain samples from patients with PD. PD patients displayed low intensities of pPAK4 and TH, whereas young controls (YC) and age-matched controls (AC) exhibited higher pPAK4 and TH levels (Fig. 1G). Overall, levels of pPAK4 and TH were positively correlated (r = 0.728) (Fig. 1G), suggesting that PAK4 also regulates TH transcription in vivo.
PAK4 upregulates dopamine synthesis through TH phosphorylation at Ser40
TH activity is regulated by phosphorylation on serine residues S19, S31, and S40 (Haycock and Haycock, 1991; Zhu et al., 2012). A search for a PAK4-mediated phosphorylation motif in TH revealed S40 and its flanking sequences in human TH as a potential candidate (Fig. 2A) (Rennefahrt et al., 2007). To determine whether PAK4 directly interacts with TH, we first performed a coimmunoprecipitation assay using rat SN lysates. As shown in Fig. 2B, PAK4 physically interacts with TH, suggesting that TH is a substrate of PAK4. To determine whether PAK4 does indeed phosphorylates TH on S40, we generated nonphosphorylatable mutant forms of TH in which each of the previously known phosphorylated residues (Haycock and Haycock, 1991), S19, S31, or S40, was replaced by alanine. An in vitro PAK4 kinase assay using recombinant proteins revealed a loss of phosphorylation in THS40A but not THS19A or THS31A mutants (Fig. 2C), identifying S40 as a target residue of PAK4. Consistent with this result, forced expression of caPAK4 in primary cultured mesencephalic neurons elevated the levels of phosphorylated THS40 (pTHS40) (Fig. 2D; quantified in Fig. 2E). Next, we examined the functional significance of this phosphorylation in the regulation of DA levels. To this end, we coexpressed caPAK4 with either THWT or THS40A and analyzed DA levels in PC12 cells. Coexpression of caPAK4 with THWT elevated DA levels ~2.4-fold compared to controls (Fig. 2F). However, expression of THS40A significantly blocked the caPAK4-induced increase in DA levels in PC12 cells (Fig. 2F). These results support the notion that PAK4 stimulates DA synthesis, at least in part, through phosphorylation of TH at S40.
Positive correlation of pPAK4 and pTHS40 in human PD brain tissues
To examine the clinical relevance of the pPAK4/pTHS40 axis, we performed immunostaining for pTHS40 in SN tissues from the human brain. Most DA cells showed strong signals for pTHS40 in the age-matched control tissues (Fig. 3A; quantified in Fig. 3B). However, the signals were heterogeneous, though overall relatively weak, in the remaining DA neurons in the PD brain (Fig. 3A; quantified in Fig. 3B). This heterogeneity in pTHS40 levels may reflect alterations in pPAK4 levels. We therefore examined phosphorylation of THS40 in relation to pPAK4 levels by double immunostaining. As shown in Fig. 3C, neuromelanin-positive DA neurons with strong (inset 1) or weak (inset 2) pPAK4 reactivity (red arrowheads) displayed corresponding signals for pTHS40 (white arrows), although no signals for either pPAK4 or pTHS40 were detected in some cells (Fig. 3C; inset 3). The levels of pPAK4 and pTHS40 showed a positive correlation (r = 0.665) (Fig. 3D), suggesting that decreased PAK4 activity in PD may partially explain the low TH activity and the resultant low DA levels. These results provide in vivo evidence for the correlation of activities between pPAK4 and pTH40. Taken together, our data demonstrate that caPAK4 can act as a stimulator of DA synthesis by elevating TH transcription and activity.
DISCUSSION
The present study unravels a novel mechanism underlying PAK4-mediated modification of PD in animal models in which caPAK4 upregulates DA levels. Expression of caPAK4 stimulated transcription of TH via the CREB transcription factor. Moreover, caPAK4 increased the catalytic activity of TH through its phosphorylation of S40, which is essential for TH activation. More importantly, these findings were recapitulated in brain tissues from PD patients; levels of pPAK4 and pTHS40 were positively correlated. Collectively, our data support the therapeutic effects of PAK4 and suggest that targeting PAK4 is a viable approach for symptomatic treatment of PD.
Previously, we demonstrated that caPAK4 elevates levels of dopamine and its metabolites in a 6-hydroxydopamine (6-OHDA)-induced PD model compared to controls (Won et al., 2016). Our interpretation was that this effect was solely due to the neuroprotective function of PAK4. In the present study, we unraveled its hidden function, demonstrating that PAK4 controls both TH activity and levels. Together, it seems likely that PAK4 may elevate dopamine levels in the 6-OHDA PD model through its neuroprotective effect on dopaminergic neurons and its regulatory effect on TH. It is thus tempting to speculate that these dual functions of PAK4 may work synergistically, resulting in significant rescue of the impaired motor behavior of 6-OHDA rats.
PAK4 regulates a number of target genes through CREB, resulting in pleiotropic effects, such as promotion of cell proliferation and neuroprotection (Won et al., 2019), but these two proteins are ubiquitously expressed. In contrast, TH is not widely expressed but only exists in certain cell types, such as DA neurons in the brain and melanocytes in the skin (Won et al., 2016; Yun et al., 2015). This restricted expression of TH may confer specificity to its PAK4-dependent regulation. Additionally, the finding that PAK4 interacts with TH in the cytoplasm adds to the specificity. Together, decreases in PAK4 and pPAK4 levels in PD may contribute to impaired movement.
Currently, the gold standard of PD treatment is DA replacement using L-dopa. However, long-term treatment with this drug frequently causes motor complications, such as an increase in motor fluctuations and dyskinesia over time. Most likely, progressive degeneration of the nigrostriatal axis explains these side effects; thus, disease-modifying treatment is critically needed. Gene therapy could be an available option for PD treatment (Wood, 2020). Current gene therapy focuses on either neuroprotective interventions that employ trophic factors, such as GDNF, BDNF, and neurturin, or DA replacement by introduction of a gene(s) for TH or amino acid decarboxylase (Axelsen and Woldbye, 2018; Bjorklund and Kordower, 2010; Denyer and Douglas, 2012). Clinical trials have shown that gene therapy for PD is safe, although its efficacy remains a hurdle. Considering its beneficial effect on DA synthesis, PAK4 might be an alternative target for DA replacement in patients with PD. Together with our previous study that defined a key role for PAK4 in dopaminergic neuron survival (Won et al., 2016), the current findings support a dual effect of PAK4 involving both neuroprotection and elevation of DA levels. In this regard, PAK4-based gene therapy may offer a disease-modifying effect for successful PD treatment.
Supplemental Materials
Note: Supplementary information is available on the Molecules and Cells website (www.molcells.org).
Article information
Articles from Mol. Cells are provided here courtesy of Mol. Cells
References
- Axelsen, T.M. and Woldbye, D.P.D. (2018). Gene therapy for Parkinson's disease, an
update. J. Parkinsons Dis.. 8, 195-215.
- Bjorklund, T. and Kordower, J.H. (2010). Gene therapy for Parkinson's disease. Mov.
Disord.. 25, S161-S173.
- Dauer, W. and Przedborski, S. (2003). Parkinson's disease: mechanisms and models.
Neuron. 39, 889-909.
- Denyer, R. and Douglas, M.R. (2012). Gene therapy for Parkinson's disease. Parkinsons
Dis.. 2012, 757305.
- Ghee, M., Baker, H., Miller, J.C., and Ziff, E.B. (1998). AP-1, CREB and CBP transcription
factors differentially regulate the tyrosine hydroxylase gene. Brain Res. Mol. Brain
Res.. 55, 101-114.
- Haycock, J.W. and Haycock, D.A. (1991). Tyrosine hydroxylase in rat brain dopaminergic
nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. J. Biol.
Chem.. 266, 5650-5657.
- Kim, T.E., Park, M.J., Choi, E.J., Lee, H.S., Lee, S.H., Yoon, S.H., Oh, C.K., Lee,
B.J., Kim, S.U., and Lee, Y.S. (2003). Cloning and cell type-specific regulation of
the human tyrosine hydroxylase gene promoter. Biochem. Biophys. Res. Commun.. 312, 1123-1131.
- Marsden, C.D. (1990). Parkinson's disease. Lancet. 335, 948-952.
- Mones, R.J., Elizan, T.S., and Siegel, G. (1970). L-dopa induced dyskinesias in 152
patients with Parkinson's disease. Trans. Am. Neurol. Assoc.. 95, 286-287.
- Nam, J.H., Park, E.S., Won, S.Y., Lee, Y.A., Kim, K.I., Jeong, J.Y., Baek, J.Y., Cho,
E.J., Jin, M., and Chung, Y.C. (2015). TRPV1 on astrocytes rescues nigral dopamine
neurons in Parkinson's disease via CNTF. Brain. 138, 3610-3622.
- Park, M.H., Lee, H.S., Lee, C.S., You, S.T., Kim, D.J., Park, B.H., Kang, M.J., Heo,
W.D., Shin, E.Y., and Schwartz, M.A. (2013). p21-Activated kinase 4 promotes prostate
cancer progression through CREB. Oncogene. 32, 2475-2482.
- Piech-Dumas, K.M. and Tank, A.W. (1999). CREB mediates the cAMP-responsiveness of
the tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-deficient
PC12 cell lines. Brain Res. Mol. Brain Res.. 70, 219-230.
- Ramsey, A.J. and Fitzpatrick, P.F. (1998). Effects of phosphorylation of serine 40
of tyrosine hydroxylase on binding of catecholamines: evidence for a novel regulatory
mechanism. Biochemistry. 37, 8980-8986.
- Rennefahrt, U.E., Deacon, S.W., Parker, S.A., Devarajan, K., Beeser, A., Chernoff,
J., Knapp, S., Turk, B.E., and Peterson, J.R. (2007). Specificity profiling of Pak
kinases allows identification of novel phosphorylation sites. J. Biol. Chem.. 282, 15667-15678.
- Tekin, I., Roskoski, R., Carkaci-Salli, N., and Vrana, K.E. (2014). Complex molecular
regulation of tyrosine hydroxylase. J. Neural Transm. (Vienna). 121, 1451-1481.
- Won, S.Y., Park, J.J., Shin, E.Y., and Kim, E.G. (2019). PAK4 signaling in health
and disease: defining the PAK4-CREB axis. Exp. Mol. Med.. 12, 1-9.
- Won, S.Y., Park, M.H., You, S.T., Choi, S.W., Kim, H.K., McLean, C., Bae, S.C., Kim,
S.R., Jin, B.K., and Lee, K.H. (2016). Nigral dopaminergic PAK4 prevents neurodegeneration
in rat models of Parkinson's disease. Sci. Transl. Med.. 8, 367ra170.
- Wood, H. (2020). Gene therapy boosts response to levodopa in patients with Parkinson
disease. Nat. Rev. Neurol.. 16, 242.
- Yun, C.Y., You, S.T., Kim, J.H., Chung, J.H., Han, S.B., Shin, E.Y., and Kim, E.G.
(2015). p21-Activated kinase 4 critically regulates melanogenesis via activation of
the CREB/MITF and β-catenin/MITF pathways. J. Invest. Dermatol.. 135, 1385-1394.
- Zhu, Y., Zhang, J., and Zeng, Y. (2012). Overview of tyrosine hydroxylase in Parkinson's
disease. CNS Neurol. Disord. Drug Targets. 11, 350-358.
